Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting
HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today …